CARB-X funds Facile Therapeutics with up to $18m

CARB-X funds US-based Facile Therapeutics to further develop a new oral drug that would disable toxins that enable C. difficile infections to recur.

CARB-X will provide Facile Therapeutics, based in Belmont, California, USA, with up to $1.26 million to develop a new orally bioavailable drug to treat recurring infections caused by Clostridium difficile. Facile could receive up to $17 million more in additional funding from CARB-X if the project achieves certain development milestones, for a potential total of $18.26 million.

Read more: https://carb-x.org/carb-x-news/carb-x-funds-facile-therapeutics-to-develop-a-new-treatment-to-prevent-recurring-c-difficile-bacterial-infections/